Producer
Zoetis Inc.
Zoetis Inc. (NYSE: ZTS; ~$8.5B revenue; Parsippany NJ) is the world's largest animal health company, spun off from Pfizer in 2013. Zoetis manufactures TROVAC-NDV and conventional inactivated AI vaccines for commercial poultry, along with broad-spectrum animal health products for livestock and companion animals across 100 countries.
4
Inputs supplied
4
Goods downstream
5
Facilities
0
Stories
What they make
4 inputs Zoetis Inc. supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
pharmaceutical
Aquaculture Vaccines (Salmon Lice and Bacterial) →
pharmaceutical
Poultry Biosecurity Inputs & HPAI Vaccines →
pharmaceutical
Swine Vaccines (PRRSV, PCV2, Mycoplasma) →
pharmaceutical
Marek's Disease Vaccine (MDV) →
Where it shows up
Goods downstream
Essential goods that depend on something Zoetis Inc. makes — pick one to see the full supply chain.
Where they make it
5 facilities
Pharmaq (Zoetis) — Chilean Salmon Vaccine Operations →
CLLos Lagos · manufacturing
Chilean production/distribution facility for Pharmaq salmon vaccines serving Chilean Atlantic salmon farming industry (second-largest globally after Norway).
Pharmaq (Zoetis) — Overhalla, Norway Salmon Vaccine Facility →
NOTrøndelag · manufacturing
Primary production site for Pharmaq (Zoetis subsidiary) salmon vaccines; produces hundreds of millions of doses annually for ISA, pancreatic disease, furunculosis, and other salmon pathogens. Norway is the origin of the world's most successful aquaculture vaccination program — reduced antibiotic use from 48 tons (1987) to <1 ton (1999).
Zoetis - Suzhou, Jiangsu China →
CNVaccine R&D and manufacturing for swine, cattle, fish, companion animals; China expansion hub
Zoetis Kalamazoo Biologics Manufacturing →
USKalamazoo, Michigan · pharmaceutical_plant
Zoetis US production hub for poultry biologics including MD-Vac CFL (cell-free HVT) and POULVAC PROCERTA HVT-IBD-ND (launched October 2022). The Kalamazoo facility is the legacy of Pfizer Animal Health's manufacturing footprint, inherited when Zoetis spun off from Pfizer in 2013.
Zoetis Lincoln NE Biologics Manufacturing →
USNebraska · lab
Zoetis biologics manufacturing in Lincoln NE — primary US site for poultry vaccine production including AI and Newcastle disease biologicals.
What else they do
Business segments
The company's full revenue map — where this supply-chain role fits within their broader business.
Livestock Vaccines
35%Companion Animal Health
35%Livestock Therapeutics
20%Diagnostics
10%
Intelligence
What's known
Sourced claims about this company's role in supply chains — chokepoints, concentration, incidents, dual-use connections.
Concentration2013
Zoetis was entirely hidden inside Pfizer as the "Animal Health" division until its IPO in February 2013 — the largest animal health IPO in history ($2.2B). Before the spinoff, investors had no visibility into the size or profitability of the global animal health market. The Zoetis IPO revealed that animal health was an approximately $22B global market growing faster than human pharma — completely invisible to capital markets while inside Pfizer. This is structurally analogous to companies like Agilent (spun from HP) or PayPal (spun from eBay) revealing hidden market scale.
US Securities and Exchange Commission ↗Did you know2023
Zoetis is publicly known for dog and cat medications, but they also control ~48% of the global salmon vaccine market — covering infectious salmon anemia (ISA), sea lice, and Yersinia infections in Norwegian and Chilean salmon farms. Norwegian salmon farming (producing ~1.3 million tonnes/year) is the world's largest aquaculture industry by value; without ISA vaccines, large-scale salmon farming would be biologically impossible (ISA causes mass mortality). Zoetis's AquaVac vaccines are mandatory inputs for global salmon supply chains. The same Zoetis that sells Apoquel for itchy dogs at US veterinary clinics also makes the vaccines that allow Norwegian salmon to be raised in offshore net pens for US and European seafood consumers. A companion animal pharmaceutical company controls a critical input for the ocean-farm food supply chain that produces salmon fillets in American restaurants.
Zoetis Inc. ↗Origin2023
Zoetis was spun off from Pfizer in 2013 — Pfizer's strategic rationale was unlocking shareholder value by separating a faster-growing animal health business. But the spinoff also revealed the cross-subsidy that had been happening inside Pfizer: Pfizer's human pharmaceutical R&D had generated drug candidates that failed in human medicine but worked in animal medicine, or vice versa. Apoquel (oclacitinib) — Zoetis's most commercially successful companion animal product (~$1B/yr for dog allergies) — is a JAK1 selective inhibitor. The same JAK inhibitor drug class in human medicine produced ruxolitinib (myelofibrosis), tofacitinib (rheumatoid arthritis), baricitinib (COVID-19), and upadacitinib (atopic dermatitis). The drug discovery infrastructure Pfizer built for human JAK inhibitor development (for arthritis and cancer) produced the veterinary drug that became the most important pet allergy medication in history. Pfizer's human oncology R&D created a pet dermatology medication — the boundary between animal and human pharmaceutical innovation is more permeable than most people realize.
Zoetis Inc. ↗